Volume 12 Number 7/8 July/August 2011

6th IAS Conference on HIV Pathogenesis, Treatment and Prevention 17-–20 July 2011, Rome

Webcasts for major research at IAS

Treatment is prevention: ARV treatment in HPTN-052 reduces transmission by at least 96%: single transmission in treatment arm occurred before viral suppression

Daily oral tenofovir/FTC PrEP reduces heterosexual transmission by 63% in the TDF2 study

Tenofovir/FTC vs tenofovir as daily oral PrEP: preliminary results from Partners PrEP

Elvitegravir vs raltegravir: 48 week results in treatment-experienced patients

Dolutegravir: 48 week results from phase II study in treatment-naive patients

Lersivirine: 48 week results compared to efavirenz in phase 2 treatment-naive study

Maraviroc plus atazanavir/r without nukes versus standard of care: 48 week results

SPARTAC trial: treatment in primary infection for 48 weeks shows small delay in disease progression

Hearing loss not associated with HIV in MACS and WIHS cohorts

Pharmacokinetics of darunavir and fosamprenavir in pregnancy

Low birth weight and preterm delivery

Hormonal contraception and HIV transmission risk

No difference in AIDS-free survival in children starting ART with a CD4% between 15%–24% compared to deferring until less than 15% in the PREDICT trial

Paediatric antiretroviral pipeline: update on etravirine and maraviroc

Prematurity not associated with early mortality in infants on ART

More metabolic abnormalities in children receiving a PI compared to NNRTI in NEVEREST study

Free online resource for treatment decisions without access to genotype resistance tests

17th Annual Conference of the British HIV Association (BHIVA) 6-–8 April 2011, Bournemouth

Treatment in seroconversion maintains HIV specific immune responses similar to long term slow progressors

18th Conference on Retroviruses and Opportunistic Infections (CROI) 27 February-–3 March 2011, Boston

Monitoring treatment in resource limited settings: results from PHPT-3 and Stratall ANRS12110/ESTER trials

DART: high rates of viral suppression after five years and a single CD4 test with a threshold of 250 cells/mm3 could reduce unnecessary switching

Lopinavir/r monotherapy used as second-line therapy in resource-limited settings

Treating children previously exposed to single dose nevirapine: update on IMPAACT P1060 and NEVEREST

Lopinavir/ritonavir oral solution toxicity in neonates

Paediatric antiretroviral pipeline: darunavir and raltegravir

FDA approve new NNRTI rilpivirine (Edurant) in the US

Gilead signs up for Medicines Patent Pool

FDA approve new NNRTI-based fixed dose combination of rilpivirine/tenofovir/FTC (Complera) in the US

FDA approval of generic ARVs

FDA approve boceprevir (Victrelis) for HCV

FDA approve telaprevir (Incivek) to treat hepatitis C

FDA supplemental information about using boceprevir and telaprevir

Interactions between multivitamins or acid reducing agents and dolutegravir (S/GSK1349572)

HPTN 052 study stopped early: significant reduction in HIV transmission from early use of HIV treatment in serodifferent partners

Lopinavir and rifampicin interaction in HIV-positive patients

Case report:– Cushing’s syndrome with atazanavir/ritonavir

HTB supplement: 2011 pipeline report

Treatment as prevention: online presentations

CCR5 tropism guidelines

UN High Level Meeting on HIV and AIDS

Pharmacokinetics of different rifabutin dosing strategies with lopinavir/ritonavir-based ART

Initiation of ART during breastfeeding can induce multidrug resistance in infants

Volume 12 Number 7/8 July/August 2011 PDF

HTB supplement: 2011 pipeline report

Introduction and executive summary

HIV point of care diagnostics pipeline

The tuberculosis treatment pipeline

The hepatitis C treatment pipeline



The paediatric antiretroviral pipeline

The antiretroviral pipeline

Preventive technologies, immune-based and gene therapies, and research towards a cure

The tuberculosis diagnostic pipeline

The tuberculosis vaccine pipeline

Patents and the pipeline: is access under threat?

2011 pipeline report PDF

Volume 13 Number 5/6 May/June 2011

Job vacancy: Treatment activist post at i-Base

First Workshop on Nanomedicine for Infectious Diseases of Poverty, 27–-31 March 2011, Magaliesberg, South Africa

17th Annual Conference of the British HIV Association (BHIVA), 6-8 April 2011, Bournemouth

Post navigation